NCT01196208 2020-09-21A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001Seagen Inc.No longer available
NCT00051597 2011-10-12A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic MalignanciesSeagen Inc.Phase 1/2 Completed70 enrolled